Clinical trial NCT00860548 - References

Scleroderma, Systemic — SCOT Scleroderma Treatment Alternative Registry (STAR Registry)

Citation(s)

•   Bulpitt KJ, Clements PJ, Lachenbruch PA, Paulus HE, Peter JB, Agopian MS, Singer JZ, Steen VD, Clegg DO, Ziminski CM, Alarcon GS, Luggen ME, Polisson RP, Willkens RF, Reading JC, Williams HJ, Ward JR
  Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis). Ann Intern Med. 1993 Apr 15;118(8):602-9.
•   Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, Wigley F, Weisman M, Barr W, Moreland L, Medsger TA Jr, Steen V, Martin R, Collier D, Weinstein A, Lally E, Varga J, Weiner S, Andrews B, Abeles M, Seibold J
  Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis. Arthritis Rheum. 1999 Nov;42(11):2372-80.
•   Czirják L, Nagy Z, Szegedi G
  Survival analysis of 118 patients with systemic sclerosis. J Intern Med. 1993 Sep;234(3):335-7.
•   Follansbee WP, Zerbe TR, Medsger TA Jr
  Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association. Am Heart J. 1993 Jan;125(1):194-203.
•   Lee P, Langevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M, Buskila D, Dutz JP, Khostanteen I, Piper S, et al
  Mortality in systemic sclerosis (scleroderma). Q J Med. 1992 Feb;82(298):139-48.
•   Steen VD, Mayes MD, Merkel PA
  Assessment of kidney involvement. Clin Exp Rheumatol. 2003;21(3 Suppl 29):S29-31. Review.

An Observational, Long-term Follow-up Study of Eligible Individuals Declining To Participate in the Scleroderma Cyclophosphamide or Transplantation (SCOT) Study (SCSSc-02)

Details for clinical trial NCT00860548